RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More informationThe U.S. Food and Drug Administration (FDA) has rolled out “agentic AI” to support staff across the agency — marking a major step in its internal AI rollout.
The International Council for Harmonisation (ICH) held its 2025 Assembly in Singapore, completing major guideline decisions and welcoming new members.
ICH expands its global regulatory network by admitting new members and observers during its November 2025 meeting.
The EMA’s PRAC met 24–27 November to review safety-related issues for authorised medicines — concluding no new referral procedures, but continuing ongoing assessments and routine pharmacovigilance tasks.
A major study offers new insight into how vaccine-derived poliovirus type 2 spreads and what this means for global eradication.
The MHRA sets out new steps to modernise the UK’s medical technology regulatory framework.
The MHRA Inspectorate clarifies updated insurance requirements for Phase 1 clinical trials ahead of the 2026 regulations.
The MHRA has launched a strategy blog series bringing together external voices to discuss the future direction of UK medicines and medical devices regulation.
Professor Alastair Denniston sets out core principles for a new UK framework to regulate AI in healthcare so it is safe, fast and trusted.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended ten new medicines for approval and four extensions of indication at its November 2025 session.